249 related articles for article (PubMed ID: 31548341)
41. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
42. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
[TBL] [Abstract][Full Text] [Related]
43. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
44. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
45. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sukswai N; Aung PP; Yin CC; Li S; Wang W; Wang SA; Ortega V; Lyapichev K; Nagarajan P; Alfattal R; Angelova E; Tang Z; Loghavi S; Kanagal-Shamanna R; Miranda RN; Pemmaraju N; Bhalla K; Konopleva M; Medeiros LJ; Khoury JD
Am J Surg Pathol; 2019 Oct; 43(10):1429-1437. PubMed ID: 31261288
[TBL] [Abstract][Full Text] [Related]
46. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
47. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
48. Blastic Plasmacytoid Dendritic Cell Neoplasm: Underlining the importance of an early diagnosis and the use of tagraxofusp therapy before wide dissemination.
Massone C; Raiola AM; Dominietto A; Minetto P; Beltramini S; Cerroni L; Sola S; Angelucci E
Australas J Dermatol; 2021 May; 62(2):e316-e318. PubMed ID: 32757292
[No Abstract] [Full Text] [Related]
49. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel AE; Woo JH; Ahn C; Pemmaraju N; Medeiros BC; Carraway HE; Frankfurt O; Forman SJ; Yang XA; Konopleva M; Garnache-Ottou F; Angelot-Delettre F; Brooks C; Szarek M; Rowinsky E
Blood; 2014 Jul; 124(3):385-92. PubMed ID: 24859366
[TBL] [Abstract][Full Text] [Related]
50. [Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Sang W; Wang CF; Cheng YF; Liu X; Li XX; Gulinar A; Li JZ; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):326-30. PubMed ID: 22883672
[TBL] [Abstract][Full Text] [Related]
51. Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm.
Díaz Acedo R; Domínguez Muñoz MÁ; Navajas Laguna C; Morales Camacho R; Simón Pilo I; Calama Ruiz-Mateos VP; Yébenes Ramírez M; Vahí Sánchez de Medina M; Artacho Criado S; Rodríguez Pérez A; Couto Caro MC
Leuk Lymphoma; 2022 Jul; 63(7):1762-1764. PubMed ID: 35200083
[No Abstract] [Full Text] [Related]
52. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
53. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Wang SY; Thomassen K; Kurch L; Opitz S; Franke GN; Bach E; Platzbecker U; Kayser S
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e579-e582. PubMed ID: 33795208
[No Abstract] [Full Text] [Related]
54. Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report.
Sibai J; Chen R; Nabhani IA; Perusini MA; Sibai H
EJHaem; 2022 Nov; 3(4):1374-1376. PubMed ID: 36467820
[TBL] [Abstract][Full Text] [Related]
55. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
56. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.
Bastidas Torres AN; Cats D; Mei H; Fanoni D; Gliozzo J; Corti L; Paulli M; Vermeer MH; Willemze R; Berti E; Tensen CP
Genes Chromosomes Cancer; 2020 May; 59(5):295-308. PubMed ID: 31846142
[TBL] [Abstract][Full Text] [Related]
57. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
58. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
[TBL] [Abstract][Full Text] [Related]
59. Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.
Li Y; Sun V; Sun W; Pawlowska A
Hematol Oncol Clin North Am; 2020 Jun; 34(3):601-612. PubMed ID: 32336423
[TBL] [Abstract][Full Text] [Related]
60. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
